GB002 (seralutinib) clinical trials

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

This study looks at the long-term effects of a drug called GB002 (seralutinib) for people with Pulmonary Arterial Hypertension (PAH). Participants have already been part of a previous GB002 study. It's an open-label study, meaning everyone knows they are receiving the drug.